The Right Place and Time for Applied Molecular Evolution
Executive Summary
Applied Molecular Evolution is a company seemingly in the right place, with the right technology, at the right time--a beneficiary of Big Pharma's current search for ways to short-cut the discovery process. In the last three months, AME received initial product development milestones from two deals and filed an IND on its own lead product candidate, an improved version of Remicade. Those events validated its technology for optimizing proteins-enough so that partner Eli Lilly decided to buy the firm outright.
You may also be interested in...
Deal Statistics Quarterly, Q4 2003
In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2003. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Deal Statistics Quarterly, Q4 2003
In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2003. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Practical Dealmaking in Discovery: The Structural Biology Case
Discovery dealmaking is by no means dead-but it's certainly been practicalized. In the last few months, one good example of a still interesting discovery area--high-throughput structural biology--has seen a flurry of dealmaking. But it's not yet frequent or rich enough to justify the venture valuations originally applied to them. And the deals themselves reflect the results-oriented conservatism of Big Pharma buyers.